New drug AB821 enters first human tests for advanced melanoma
NCT ID NCT07027488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AB821 (a drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced melanoma and other immune-responsive solid tumors.
- What could go wrong
- This is a very early Phase 1 trial with only 50 participants, so it is primarily testing safety. The drug may not shrink tumors or may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Drug combo shrink lung tumors before surgery?
- Can a Cell-Derived vaccine hold lung cancer at bay?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a Bag-Like device pull bladder tumors out whole?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer